Target intelligence / Profile preview

Ribosomal protein L21 pseudogene 23 (RPL21P23)

Target
RPL21P23
Molecular classification
Other, Processed pseudogene
01

Overview

Ribosomal protein L21 pseudogene 23 is a processed pseudogene derived from the ribosomal protein L21 (RPL21) gene, located in the human genome. It does not code for a functional protein and is considered non-coding, carrying disabling mutations that prevent translation. While the functional RPL21 protein forms part of the large 60S ribosomal subunit involved in protein synthesis, the pseudogene itself has no established molecular function or clinical significance. RPL21P23 (NCBI Gene: 100270879, Ensembl: ENSG00000236776) is annotated as a pseudogene and is not listed as encoding a protein or possessing regulatory function. Pseudogenes of ribosomal proteins are numerous in the human genome, often arising through retrotransposition and are not generally transcribed into functional proteins. No structured clinical, pharmacological, or molecular research exists linking RPL21P23 to diseases, drug responses, or biomarkers; it is not included in therapeutic target databases or disease association studies. Functional ribosomal protein L21 (RPL21) is a bona fide ribosomal protein of the 60S subunit, with clinical implications for mutations (e.g., Hypotrichosis simplex of the scalp), but there is no such evidence for any of its pseudogenes, including RPL21P23.

Other names
RPL21P23RPL21_2_54

Beyond the preview

Go deeper on Ribosomal protein L21 pseudogene 23 (RPL21P23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L21 pseudogene 23 (RPL21P23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call